<link rel="stylesheet" href="/res/styles.39be4579664c3a48.css">
Artículo

TMPyP‐mediated photoinactivation of Pseudomonas aeruginosa improved in the presence of a cationic polymer

Campagno, Luciana Paula Icon; Quiroga, Ezequiel Dario Icon; Durantini, Edgardo Néstor Icon; Alovero, Fabiana Icon

Otros responsables

Fecha

05/2024

Editorial

Wiley Blackwell Publishing, Inc

Revista

Photochemistry and Photobiology

Título del libro

Nombre del evento

Fecha del evento

Institución organizadora

ISSN

0031-8655

eISSN

ISBN

Idioma

Inglés

Tipo del evento

Clasificación temática

Resumen

Pseudomonas aeruginosa is one of the most refractory organisms to antibiotic treatment and appears to be one of the least susceptible to photodynamic treatment. TMPyP is effective in the photoinactivation of P. aeruginosa, and the coadministration with the cationic polymer Eudragit®-E100 (Eu) potentiates this effect against isolates both sensitive and resistant to antibiotics. The fluorescent population (>98%) observed by flow cytometry after exposure to Eu + TMPyP remained unchanged after successive washings, indicating a stronger interaction/internalization of TMPyP in the bacteria, which could be attributed to the rapid neutralization of surface charges. TMPyP and Eu produced depolarization of the cytoplasmic membrane, which increased when both cationic compounds were combined. Using confocal laser scanning microscopy, heterogeneously distributed fluorescent areas were observed after TMPyP exposure, while homogeneous fluorescence and enhanced intensity were observed with Eu + TMPyP. The polymer caused alterations in the bacterial envelopes that contributed to a deeper and more homogeneous interaction/internalization of TMPyP, leading to a higher probability of damage by cytotoxic ROS and explaining the enhanced result of photodynamic inactivation. Therefore, Eu acts as an adjuvant without being by itself capable of eradicating this pathogen. Moreover, compared with other therapies, this combinatorial strategy with a polymer approved for pharmaceutical applications presents advantages in terms of toxicity risks.

Aprobación

Revisión

Complementado por

Referenciado por

Licencia Creative Commons

Excepto donde se indique lo contrario, la licencia de este ítem se describe como by-nc-sa